NKTX Strangle Strategy
NKTX (Nkarta, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
NKTX (Nkarta, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $166.7M, a beta of 0.94 versus the broader market, a 52-week range of 1.7-3.72, average daily share volume of 766K, a public-listing history dating back to 2020, approximately 108 full-time employees. These structural characteristics shape how NKTX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.94 places NKTX roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on NKTX?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
NKTX snapshot
As of August 14, 2026, spot at $2.32, ATM IV 190.50%, IV rank 47.73%, expected move 54.61%. The strangle on NKTX below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this strangle structure on NKTX specifically: NKTX IV at 190.50% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 54.61% (roughly $1.27 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated NKTX expiries trade a higher absolute premium for lower per-day decay. Position sizing on NKTX should anchor to the underlying notional of $2.32 per share and to the trader's directional view on NKTX stock.
NKTX strangle setup
The NKTX strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With NKTX at $2.32 on that close, the first option leg uses a $2.44 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed NKTX chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 NKTX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $2.44 | N/A |
| Buy 1 | Put | $2.20 | N/A |
NKTX strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
NKTX strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on NKTX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on NKTX
Strangles on NKTX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the NKTX chain.
NKTX thesis for this strangle
The market-implied 1-standard-deviation range for NKTX extends from approximately $1.05 on the downside to $3.59 on the upside. A NKTX long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current NKTX IV rank near 47.73% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on NKTX should anchor more to the directional view and the expected-move geometry. As a Healthcare name, NKTX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to NKTX-specific events.
NKTX strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. NKTX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move NKTX alongside the broader basket even when NKTX-specific fundamentals are unchanged. Always rebuild the position from current NKTX chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on NKTX?
- A strangle on NKTX is the strangle strategy applied to NKTX (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With NKTX stock at $2.32 on the most recent close, the strikes shown on this page are snapped to the nearest listed NKTX chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are NKTX strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the NKTX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 190.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a NKTX strangle?
- The breakeven for the NKTX strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The NKTX market-implied 1-standard-deviation expected move in the same options snapshot is approximately 54.61%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on NKTX?
- Strangles on NKTX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the NKTX chain.
- How does current NKTX implied volatility affect this strangle?
- NKTX ATM IV is at 190.50% with IV rank near 47.73%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.